Failure of prophylaxis against PCP in patients with HIV infection

Stefano Bonora, Giovanni Di Perri, Sandro Vento, Angelo Cazzadori, Ercole Concia

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Since the end of the 1980s, primary anti-Pneumocystis carinii pneumonia (PCP) prophylaxis has become a fundamental part of the global AIDS control strategy in industrialized countries. The widespread adoption of anti-PCP chemoprophylaxis has been a key element in prolonging the survival of patients with AIDS. There is general agreement on the need to begin chemoprophylaxis when individual CD4+ cell counts drop below the value of 200/μL. However, PCP still develops in up to 27% of susceptible HIV- infected patients despite regular prophylaxis intake. Failure of chemoprophylaxis may depend on different factors. The choice of the regimen and the patient's compliance to it have been the first variables to be identified, whereas the importance of the residual cellular immune function as complementary protective mechanism against PCP has emerged in subsequent clinical studies. Albeit of limited general concern, issues such as P. carinii drug resistance and defective drug absorption may play some role in prophylaxis failure in selected patients. Regarding the epidemiology of primary and recurrent episodes of PCP, recent studies based on genetic fingerprinting techniques revealed that interhuman transmission of the organism could be more relevant than so far expected, thus raising some concern of the possibility of nosocomial spread among susceptible individuals. The downgrading tendency of immune competence in HIV infection and the related increasing risk of developing PCP make it possible to envisage a two-step chemoprophylactic strategy, with the most effective compound, cotrimoxazole, to be reserved for the last and most risky disease stage, when immune response no longer provides any support for preventing the development of PCP.

Original languageEnglish
Pages (from-to)843-848
Number of pages6
JournalAIDS Patient Care and STDs
Volume12
Issue number11
Publication statusPublished - Nov 1998
Externally publishedYes

Fingerprint

Pneumocystis Pneumonia
HIV Infections
Chemoprevention
Acquired Immunodeficiency Syndrome
Genetic Techniques
Pneumocystis carinii
DNA Fingerprinting
Sulfamethoxazole Drug Combination Trimethoprim
CD4 Lymphocyte Count
Patient Compliance
Developed Countries
Drug Resistance
Mental Competency
Epidemiology
HIV
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Leadership and Management
  • Nursing(all)

Cite this

Bonora, S., Di Perri, G., Vento, S., Cazzadori, A., & Concia, E. (1998). Failure of prophylaxis against PCP in patients with HIV infection. AIDS Patient Care and STDs, 12(11), 843-848.

Failure of prophylaxis against PCP in patients with HIV infection. / Bonora, Stefano; Di Perri, Giovanni; Vento, Sandro; Cazzadori, Angelo; Concia, Ercole.

In: AIDS Patient Care and STDs, Vol. 12, No. 11, 11.1998, p. 843-848.

Research output: Contribution to journalArticle

Bonora, S, Di Perri, G, Vento, S, Cazzadori, A & Concia, E 1998, 'Failure of prophylaxis against PCP in patients with HIV infection', AIDS Patient Care and STDs, vol. 12, no. 11, pp. 843-848.
Bonora S, Di Perri G, Vento S, Cazzadori A, Concia E. Failure of prophylaxis against PCP in patients with HIV infection. AIDS Patient Care and STDs. 1998 Nov;12(11):843-848.
Bonora, Stefano ; Di Perri, Giovanni ; Vento, Sandro ; Cazzadori, Angelo ; Concia, Ercole. / Failure of prophylaxis against PCP in patients with HIV infection. In: AIDS Patient Care and STDs. 1998 ; Vol. 12, No. 11. pp. 843-848.
@article{e300fbcf20a64d45b7c644cb50cd8ed2,
title = "Failure of prophylaxis against PCP in patients with HIV infection",
abstract = "Since the end of the 1980s, primary anti-Pneumocystis carinii pneumonia (PCP) prophylaxis has become a fundamental part of the global AIDS control strategy in industrialized countries. The widespread adoption of anti-PCP chemoprophylaxis has been a key element in prolonging the survival of patients with AIDS. There is general agreement on the need to begin chemoprophylaxis when individual CD4+ cell counts drop below the value of 200/μL. However, PCP still develops in up to 27{\%} of susceptible HIV- infected patients despite regular prophylaxis intake. Failure of chemoprophylaxis may depend on different factors. The choice of the regimen and the patient's compliance to it have been the first variables to be identified, whereas the importance of the residual cellular immune function as complementary protective mechanism against PCP has emerged in subsequent clinical studies. Albeit of limited general concern, issues such as P. carinii drug resistance and defective drug absorption may play some role in prophylaxis failure in selected patients. Regarding the epidemiology of primary and recurrent episodes of PCP, recent studies based on genetic fingerprinting techniques revealed that interhuman transmission of the organism could be more relevant than so far expected, thus raising some concern of the possibility of nosocomial spread among susceptible individuals. The downgrading tendency of immune competence in HIV infection and the related increasing risk of developing PCP make it possible to envisage a two-step chemoprophylactic strategy, with the most effective compound, cotrimoxazole, to be reserved for the last and most risky disease stage, when immune response no longer provides any support for preventing the development of PCP.",
author = "Stefano Bonora and {Di Perri}, Giovanni and Sandro Vento and Angelo Cazzadori and Ercole Concia",
year = "1998",
month = "11",
language = "English",
volume = "12",
pages = "843--848",
journal = "AIDS Patient Care and STDs",
issn = "1087-2914",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Failure of prophylaxis against PCP in patients with HIV infection

AU - Bonora, Stefano

AU - Di Perri, Giovanni

AU - Vento, Sandro

AU - Cazzadori, Angelo

AU - Concia, Ercole

PY - 1998/11

Y1 - 1998/11

N2 - Since the end of the 1980s, primary anti-Pneumocystis carinii pneumonia (PCP) prophylaxis has become a fundamental part of the global AIDS control strategy in industrialized countries. The widespread adoption of anti-PCP chemoprophylaxis has been a key element in prolonging the survival of patients with AIDS. There is general agreement on the need to begin chemoprophylaxis when individual CD4+ cell counts drop below the value of 200/μL. However, PCP still develops in up to 27% of susceptible HIV- infected patients despite regular prophylaxis intake. Failure of chemoprophylaxis may depend on different factors. The choice of the regimen and the patient's compliance to it have been the first variables to be identified, whereas the importance of the residual cellular immune function as complementary protective mechanism against PCP has emerged in subsequent clinical studies. Albeit of limited general concern, issues such as P. carinii drug resistance and defective drug absorption may play some role in prophylaxis failure in selected patients. Regarding the epidemiology of primary and recurrent episodes of PCP, recent studies based on genetic fingerprinting techniques revealed that interhuman transmission of the organism could be more relevant than so far expected, thus raising some concern of the possibility of nosocomial spread among susceptible individuals. The downgrading tendency of immune competence in HIV infection and the related increasing risk of developing PCP make it possible to envisage a two-step chemoprophylactic strategy, with the most effective compound, cotrimoxazole, to be reserved for the last and most risky disease stage, when immune response no longer provides any support for preventing the development of PCP.

AB - Since the end of the 1980s, primary anti-Pneumocystis carinii pneumonia (PCP) prophylaxis has become a fundamental part of the global AIDS control strategy in industrialized countries. The widespread adoption of anti-PCP chemoprophylaxis has been a key element in prolonging the survival of patients with AIDS. There is general agreement on the need to begin chemoprophylaxis when individual CD4+ cell counts drop below the value of 200/μL. However, PCP still develops in up to 27% of susceptible HIV- infected patients despite regular prophylaxis intake. Failure of chemoprophylaxis may depend on different factors. The choice of the regimen and the patient's compliance to it have been the first variables to be identified, whereas the importance of the residual cellular immune function as complementary protective mechanism against PCP has emerged in subsequent clinical studies. Albeit of limited general concern, issues such as P. carinii drug resistance and defective drug absorption may play some role in prophylaxis failure in selected patients. Regarding the epidemiology of primary and recurrent episodes of PCP, recent studies based on genetic fingerprinting techniques revealed that interhuman transmission of the organism could be more relevant than so far expected, thus raising some concern of the possibility of nosocomial spread among susceptible individuals. The downgrading tendency of immune competence in HIV infection and the related increasing risk of developing PCP make it possible to envisage a two-step chemoprophylactic strategy, with the most effective compound, cotrimoxazole, to be reserved for the last and most risky disease stage, when immune response no longer provides any support for preventing the development of PCP.

UR - http://www.scopus.com/inward/record.url?scp=0031754742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031754742&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 843

EP - 848

JO - AIDS Patient Care and STDs

JF - AIDS Patient Care and STDs

SN - 1087-2914

IS - 11

ER -